Inotek Pharma Cmn (ITEK) 8.76 $ITEK Inotek Phar
Post# of 273319
Posted On: 09/25/2016 5:08:06 PM
Inotek Pharma Cmn (ITEK) 8.76 $ITEK
Inotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BusinessWire - Tue Sep 06, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P. Southwell, President and Chief Executive Officer, and Claudine Prowse, PhD, Vice President, Strategy and IRO, are scheduled to participate at the following investor conferences:
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Announces the Completion of the Recruitment Phase of MATrX-1, the First Phase 3 Clinical Trial of Trabodenoson for Glaucoma
BusinessWire - Wed Aug 24, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the completion of the active recruitment phase of MATrX-1, the first pivotal Phase 3 trial of trabodenoson for the treatment of glaucoma. Trabodenoson, the Company's lead clinical candidate, is a first-in-class selective adenosine A1 mimetic under investigation for reduction of intraocular pressure (IOP) which has been observed in Phase 2 clinical trials to reduce IOP. Top-line data from the MATrX-1 study are expected in December 2016.
ITEK: 8.76 (-0.14)
Kalytera Therapeutics Appoints Dr. Andrew Salzman as Chief Medical Officer
Marketwire Canada - Tue Aug 23, 7:30AM CDT
MANHATTAN BEACH, CA--(Marketwired - Aug 23, 2016) - Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Andrew L. Salzman, M.D. as Kalytera's Chief Medical Officer. In this role, Dr. Salzman will lead efforts to advance Kalytera's drug candidates into human clinical studies.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Corporation Reports Second Quarter 2016 Financial Results and Operational Highlights
BusinessWire - Wed Aug 10, 6:00AM CDT
---Phase 3 MATrX-1 Trial of Trabodenoson in Glaucoma on Track for Completion in 4Q 2016-
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Announces Pricing of $50.0 Million of 5.75% Convertible Senior Notes due 2021
BusinessWire - Tue Aug 02, 6:01AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) (the "Company"
today announced the pricing of an underwritten public offering of $50.0 million aggregate principal amount of 5.75% Convertible Senior Notes due 2021 (the "Notes" . The Company has granted the underwriters a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of Notes. The offering is expected to close on or about August 5, 2016, subject to customary closing conditions. Cowen and Company, LLC and Piper Jaffray & Co. are acting as joint book-running managers. Perella Weinberg Partners LP and J. Wood Capital Advisors LLC are serving as financial advisors to the Company in connection with the offering.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Announces Proposed Public Offering of $50 Million of Convertible Senior Notes due 2021
BusinessWire - Mon Aug 01, 6:01AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) (the "Company" has commenced an underwritten public offering of $50 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes" , which includes the grant to the underwriters of a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of Notes.
ITEK: 8.76 (-0.14)
inVentiv Health Elects David Southwell to Company's Board of Directors
PR Newswire - Thu May 26, 8:00AM CDT
inVentiv Health, Inc., a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market, today announced that David Southwell has been elected to its Board of Directors, effective immediately. Mr. Southwell will also serve as the Chairman of the Audit Committee.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals reports 1Q loss
Automated Insights - Wed May 11, 6:07AM CDT
LEXINGTON, Mass. (AP) _ Inotek Pharmaceuticals Corp. (ITEK) on Wednesday reported a loss of $10.1 million in its first quarter.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights
BusinessWire - Wed May 11, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today reported financial results and operational highlights for the quarter ended March 31, 2016.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
BusinessWire - Tue Apr 26, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced three poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting to be held May 1-5 at the Washington State Convention Center. The presentation details are as follows:
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Corporation Announces Publication of Phase 1 Data for Trabodenoson in Healthy Adult Volunteers in the Journal of Ocular Pharmacology and Therapeutics
BusinessWire - Thu Apr 21, 6:00AM CDT
Inotek Pharmaceuticals Corporation (the "Company" or "Inotek" (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the Journal of Ocular Pharmacology and Therapeutics (JOPT) has published the results from its Phase 1 dose-escalation trial in healthy adult volunteers of the Company's lead product candidate, trabodenoson. These results support the ongoing clinical development of trabodenoson as a novel treatment for glaucoma, and follow publication of the Phase 2 study in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), announced on April 11, 2016.
ITEK: 8.76 (-0.14)
Glaucoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/7v2mrr/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AC Immune SA - Acadia Pharmaceuticals Inc. - Advanced Refractive Technologies, Inc. - Aerie Pharmaceuticals, Inc. - Allergan Plc - Altacor Limited - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Glaukos Corporation - GliaCure Inc. - Handok Inc. - Icon Bioscience, Inc. - IMMD Inc. - InMed Pharmaceuticals Inc. - Inotek Pharmaceuticals Corporation - (30 Others) Key Topics Covered: - Introduction - Glaucoma Overview - Therapeutics Development - Pipeline Products for Glaucoma - Overview - Pipeline Products for Glaucoma - Comparative Analysis - Glaucoma - Therapeutics under Development by Companies - Glaucoma - Therapeutics under Investigation by Universities/Institutes - Glaucoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Glaucoma - Products under Development by Companies - Glaucoma - Products under Investigation by Universities/Institutes - Glaucoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/7v2mrr/glaucoma
CANF: 2.63 (-0.05), AGN: 243.94 (+0.51), ACAD: 34.98 (unch), ITEK: 8.76 (-0.14), GILD: 81.37 (-0.15), GKOS: 39.15 (+0.20), AERI: 39.07 (+1.02), CLBS: 4.88 (+0.25)
Inotek Pharmaceuticals to Present at Glaucoma 360 New Horizons Forum
BusinessWire - Thu Jan 28, 6:00AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Cadmus Rich, M.D., Vice President, Medical Affairs and Clinical Development of Inotek, will present at Glaucoma 360: New Horizons Forum. The Forum is part of the Glaucoma Research Foundation's 5th Annual Glaucoma 360 meeting on Friday, January 29, 2016 at the Palace Hotel in San Francisco, California.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals elects Carsten Boess to board & audit committee
M2 - Wed Jan 13, 4:27AM CST
Biopharmaceutical company Inotek Pharmaceuticals (NasdaqGM:ITEK) on Tuesday reported the addition of Carsten Boess to its board of directors and to its Audit Committee.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Appoints Carsten Boess to Board of Directors
BusinessWire - Tue Jan 12, 6:00AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Carsten Boess has been appointed to its Board of Directors and the Audit Committee of Inotek's Board.
ITEK: 8.76 (-0.14)
Inotek to Webcast First Research and Development Day
BusinessWire - Wed Dec 16, 8:03AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced it will host its first R&D Day from 10:00 a.m. to 1:30 p.m. EST on December 17th in New York City. Members of the Inotek management team and distinguished guest speakers will provide an overview of glaucoma and other optic nerve neuropathies, and the Company's lead product candidate, trabodenoson, a first-in-class selective adenosine mimetic currently in Phase 3 development.
ITEK: 8.76 (-0.14)
Inotek to Host First Research and Development Day in New York City on December 17th, 2015
BusinessWire - Wed Nov 25, 6:00AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that it will host its first R&D Day on Thursday, December 17, 2015, from 10:00 a.m. to 1:30 p.m. EST in New York City. Members of the Inotek management team and distinguished guest speakers will provide an overview of glaucoma and other optic nerve neuropathies, and the Company's lead product candidate, trabodenoson, a first-in-class selective adenosine mimetic currently in Phase 3 development.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals to Present at the Piper Jaffray 27th Annual Healthcare Conference
BusinessWire - Tue Nov 24, 6:00AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the "Company" or "Inotek" , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Inotek senior management, including David P. Southwell, President and Chief Executive Officer, William K. McVicar, Ph.D., Executive Vice President, Chief Scientific Officer, and Claudine Prowse, Ph.D., Vice President, Strategy and Investor Relations Officer, will participate in a fireside chat discussion at the Piper Jaffray 27th Annual Healthcare Conference on December 2, 2015, at 12:00 p.m. Eastern Time at The New York Palace, in New York, NY.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BusinessWire - Tue Sep 06, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P. Southwell, President and Chief Executive Officer, and Claudine Prowse, PhD, Vice President, Strategy and IRO, are scheduled to participate at the following investor conferences:
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Announces the Completion of the Recruitment Phase of MATrX-1, the First Phase 3 Clinical Trial of Trabodenoson for Glaucoma
BusinessWire - Wed Aug 24, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the completion of the active recruitment phase of MATrX-1, the first pivotal Phase 3 trial of trabodenoson for the treatment of glaucoma. Trabodenoson, the Company's lead clinical candidate, is a first-in-class selective adenosine A1 mimetic under investigation for reduction of intraocular pressure (IOP) which has been observed in Phase 2 clinical trials to reduce IOP. Top-line data from the MATrX-1 study are expected in December 2016.
ITEK: 8.76 (-0.14)
Kalytera Therapeutics Appoints Dr. Andrew Salzman as Chief Medical Officer
Marketwire Canada - Tue Aug 23, 7:30AM CDT
MANHATTAN BEACH, CA--(Marketwired - Aug 23, 2016) - Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Andrew L. Salzman, M.D. as Kalytera's Chief Medical Officer. In this role, Dr. Salzman will lead efforts to advance Kalytera's drug candidates into human clinical studies.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Corporation Reports Second Quarter 2016 Financial Results and Operational Highlights
BusinessWire - Wed Aug 10, 6:00AM CDT
---Phase 3 MATrX-1 Trial of Trabodenoson in Glaucoma on Track for Completion in 4Q 2016-
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Announces Pricing of $50.0 Million of 5.75% Convertible Senior Notes due 2021
BusinessWire - Tue Aug 02, 6:01AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) (the "Company"
today announced the pricing of an underwritten public offering of $50.0 million aggregate principal amount of 5.75% Convertible Senior Notes due 2021 (the "Notes" . The Company has granted the underwriters a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of Notes. The offering is expected to close on or about August 5, 2016, subject to customary closing conditions. Cowen and Company, LLC and Piper Jaffray & Co. are acting as joint book-running managers. Perella Weinberg Partners LP and J. Wood Capital Advisors LLC are serving as financial advisors to the Company in connection with the offering. ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Announces Proposed Public Offering of $50 Million of Convertible Senior Notes due 2021
BusinessWire - Mon Aug 01, 6:01AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) (the "Company"
has commenced an underwritten public offering of $50 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes" , which includes the grant to the underwriters of a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of Notes. ITEK: 8.76 (-0.14)
inVentiv Health Elects David Southwell to Company's Board of Directors
PR Newswire - Thu May 26, 8:00AM CDT
inVentiv Health, Inc., a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market, today announced that David Southwell has been elected to its Board of Directors, effective immediately. Mr. Southwell will also serve as the Chairman of the Audit Committee.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals reports 1Q loss
Automated Insights - Wed May 11, 6:07AM CDT
LEXINGTON, Mass. (AP) _ Inotek Pharmaceuticals Corp. (ITEK) on Wednesday reported a loss of $10.1 million in its first quarter.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights
BusinessWire - Wed May 11, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today reported financial results and operational highlights for the quarter ended March 31, 2016.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
BusinessWire - Tue Apr 26, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced three poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting to be held May 1-5 at the Washington State Convention Center. The presentation details are as follows:
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Corporation Announces Publication of Phase 1 Data for Trabodenoson in Healthy Adult Volunteers in the Journal of Ocular Pharmacology and Therapeutics
BusinessWire - Thu Apr 21, 6:00AM CDT
Inotek Pharmaceuticals Corporation (the "Company" or "Inotek"
(NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the Journal of Ocular Pharmacology and Therapeutics (JOPT) has published the results from its Phase 1 dose-escalation trial in healthy adult volunteers of the Company's lead product candidate, trabodenoson. These results support the ongoing clinical development of trabodenoson as a novel treatment for glaucoma, and follow publication of the Phase 2 study in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), announced on April 11, 2016. ITEK: 8.76 (-0.14)
Glaucoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/7v2mrr/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AC Immune SA - Acadia Pharmaceuticals Inc. - Advanced Refractive Technologies, Inc. - Aerie Pharmaceuticals, Inc. - Allergan Plc - Altacor Limited - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Glaukos Corporation - GliaCure Inc. - Handok Inc. - Icon Bioscience, Inc. - IMMD Inc. - InMed Pharmaceuticals Inc. - Inotek Pharmaceuticals Corporation - (30 Others) Key Topics Covered: - Introduction - Glaucoma Overview - Therapeutics Development - Pipeline Products for Glaucoma - Overview - Pipeline Products for Glaucoma - Comparative Analysis - Glaucoma - Therapeutics under Development by Companies - Glaucoma - Therapeutics under Investigation by Universities/Institutes - Glaucoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Glaucoma - Products under Development by Companies - Glaucoma - Products under Investigation by Universities/Institutes - Glaucoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/7v2mrr/glaucoma
CANF: 2.63 (-0.05), AGN: 243.94 (+0.51), ACAD: 34.98 (unch), ITEK: 8.76 (-0.14), GILD: 81.37 (-0.15), GKOS: 39.15 (+0.20), AERI: 39.07 (+1.02), CLBS: 4.88 (+0.25)
Inotek Pharmaceuticals to Present at Glaucoma 360 New Horizons Forum
BusinessWire - Thu Jan 28, 6:00AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Cadmus Rich, M.D., Vice President, Medical Affairs and Clinical Development of Inotek, will present at Glaucoma 360: New Horizons Forum. The Forum is part of the Glaucoma Research Foundation's 5th Annual Glaucoma 360 meeting on Friday, January 29, 2016 at the Palace Hotel in San Francisco, California.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals elects Carsten Boess to board & audit committee
M2 - Wed Jan 13, 4:27AM CST
Biopharmaceutical company Inotek Pharmaceuticals (NasdaqGM:ITEK) on Tuesday reported the addition of Carsten Boess to its board of directors and to its Audit Committee.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals Appoints Carsten Boess to Board of Directors
BusinessWire - Tue Jan 12, 6:00AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Carsten Boess has been appointed to its Board of Directors and the Audit Committee of Inotek's Board.
ITEK: 8.76 (-0.14)
Inotek to Webcast First Research and Development Day
BusinessWire - Wed Dec 16, 8:03AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced it will host its first R&D Day from 10:00 a.m. to 1:30 p.m. EST on December 17th in New York City. Members of the Inotek management team and distinguished guest speakers will provide an overview of glaucoma and other optic nerve neuropathies, and the Company's lead product candidate, trabodenoson, a first-in-class selective adenosine mimetic currently in Phase 3 development.
ITEK: 8.76 (-0.14)
Inotek to Host First Research and Development Day in New York City on December 17th, 2015
BusinessWire - Wed Nov 25, 6:00AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that it will host its first R&D Day on Thursday, December 17, 2015, from 10:00 a.m. to 1:30 p.m. EST in New York City. Members of the Inotek management team and distinguished guest speakers will provide an overview of glaucoma and other optic nerve neuropathies, and the Company's lead product candidate, trabodenoson, a first-in-class selective adenosine mimetic currently in Phase 3 development.
ITEK: 8.76 (-0.14)
Inotek Pharmaceuticals to Present at the Piper Jaffray 27th Annual Healthcare Conference
BusinessWire - Tue Nov 24, 6:00AM CST
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the "Company" or "Inotek"
, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Inotek senior management, including David P. Southwell, President and Chief Executive Officer, William K. McVicar, Ph.D., Executive Vice President, Chief Scientific Officer, and Claudine Prowse, Ph.D., Vice President, Strategy and Investor Relations Officer, will participate in a fireside chat discussion at the Piper Jaffray 27th Annual Healthcare Conference on December 2, 2015, at 12:00 p.m. Eastern Time at The New York Palace, in New York, NY. ITEK: 8.76 (-0.14)
(0)
(0)